6. References
[1] Hayashi H (2011) Lipid Metabolism and Glial Lipoproteins in the Central Nervous
System. Biol. pharm. bull. 34: 453-461.
[2] Fagan AM, Younkin LH, Morris JC et al (2000) Differences in the Aß40/ Aß42 Ratio
Associated with Cerebrospinal Fluid Lipoproteins as a Function of Apolipoprotein E
Genotype. Ann. neurol. 48: 201-210.
[3] Balazs Z, Panzenboeck u, Hammer A et al (2004) Uptake and Transport of High-Density
Lipoproteins (HDL) and HDL-Associated a-Tocopherol by an in vitro Blood-Brain
Barrier Model. J. neurochem. 89: 939-950.
[4] Swank RL (1953) Treatment of Multiple Sclerosis with Low-Fat Diet. Arch. neurol.
psych. 69: 91-103.
[5] Swank RL (1970) Multiple Sclerosis. Twenty Years on Low-Fat Diet. Arch. neurol. 23:
460-474
[6] Sinclair HM (1956) Deficiency of Essential Fatty Acids and Atherosclerosis, etcetera.
Lancet, 270: 381-383.
[7] Shore VG, Smith ME, Perret V et al (1987) Alterations in Plasma Lipoproteins and
Apolipoproteins in Experimental Allergic Encephalomyelitis. J. lipid res. 28: 119-129.
[8] Rifai N, Christenson RH, Gelman BB et al (1987) Changes in Cerebrospinal Fluid IgG
and Apoliporotein E Indices in Patients with Multiple Sclerosis during Demyelination
and Remyelination. Clin. chem. 33: 1155-1157.
[9] Gelman BB, Rifai N, Christenson RH, et al (1988) Cerebrospinal Fluid and Plasma
Apolipoproteins in Patients with Multiple Sclerosis. Ann. clin. lab. science. 18: 46-52.
[10] Carlsson J, Armstrong VW, Reiber H et al (1991) Clinical Relevance of the
Quantification of Apolipoprotien E in Cerebrospinal Fluid. Clin. chim. acta, 196: 167-
176.
[11] Karussis D, Michaelson DM, Grigoriadis N et al (2003) Lack of Apolipoprotein-E
Exarcebates Experimentally Allergic Encephalomyelitis. Mult. scler. 9: 476-480.
[12] Sena A, Bendtzen K, Cascais MJ et al (2010) Influence of Apolipoprotein E Plasma
Levels and Tobacco Smoking on the Induction of Neutralising Antibodies to Interferon-
Beta. J. neurol. 257: 1703-1707.
[13] Giubilei F, Antonioni G, Di Legge S et al (2002) Blood Cholesterol and MRI Activity in
First Clinical Episode Suggestive of Multiple Sclerosis. Acta neurol. scand. 106: 109-112.
[14] Jamroz-Wisniewska A, Beltowski J, Stemasiak Z et al (2009) Paraoxonase 1 Acitivity in
Different Types of Multiple Sclerosis. Mult.scler. 15: 399-402.
Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases
577
[15] Marrie RA, Rudick R, Horwitz R et al (2010) Vascular Comorbility is Associated with
More Rapid Disability Progression in Multiple Sclerosis. Neurology 74: 1041-1047.
[16] Weinstock-Guttman B, Zivadinov R, Mahfooz N et al (2011) Serum Lipid Profiles are
Associated with Disability and MRI Outcomes in Multiple Sclerosis. J.
neuroinflammation 8:127-133
[17] Salemi G, Gueli MC, Vitale F, et al (2010) Blood Lipids, Homocysteine, Stress Factors,
and Vitamins in Clinically Stable Multiple Sclerosis Patients. Lipids in health and
disease 9:19-21.
[18] Burwick RM, Ramsay PP, Haines JL et al (2006) ApoE Epsilon Variation in Multiple
Sclerosis Susceptibility and Disease Severity. Neurology 66: 1373-1383.
[19] Pinholt M, Frederiksen JL, Christiansen M (2006) The Association Between
Apolipoprotein E and Multiple Sclerosis. Eur. j. neur. 13: 573-580.
[20] Enzinger C, Ropele S, Strasser-Fuchs S et al (2003) Lower Levels of N-Acetylaspartate in
Multiple Sclerosis Patients with the Apolipoprotein E e4 Allele. Arch. neurol. 60:65-70.
[21] Enzinger C, Ropele S, Smith S et al (2004) Accelerated Evolution of Brain Atrophy and
“Black Holes” in MS Patients with ApoE- e4. Ann. neurol. 55:563-569.
[22] De Stefano N, Bartolozzi ML, Nacmias B et al (2004) Influence of Apolipoprotein E e4
Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis. Arch.
neurol. 61: 536-540.
[23] Kantarci OH, Hebrink DD, Achenbach SJ et al (2004) Association of ApoE
Polymorphisms with Disease Severity in MS is Limited to Women. Neurology 62: 811-
814.
[24] Sena A, Couderc R, Ferret-Sena V et al (2009) Apolipoprotein E Polymorphisms
Interacts with Cigarette Smoking in Progression of Multiple Sclerosis. Eur. j. neur. 16:
832-837.
[25] Shi J, Zhao CB, Vollmer TL et al (2008) ApoE e4 Allele is Associated with Cognitive
Impairment in Patients with Multiple Sclerosis. Neurology, 70: 185-190.
[26] Koutsis G, Panas M, Giogkaraki E et al (2009) An ApoAI Promoter Polymorphism is
Associated with Cognitive Performance in Patientswith Multiple Sclerosis. Mult. scler.
15: 174-179.
[27] Sena A, Pedrosa R, Ferret-Sena V et al (2000) Interferon ß1a Therapy Changes
Lipoprotein Metabolism in Patients with Multiple Sclerosis. Clin. chem. lab. med. 38:
209-213.
[28] Morra BV, Coppola G, Orefice G et al (2004) Interferon ß Treatment Decreases
Cholesterol Plasma Levels in Multiple Sclerosis Patients. Neurology 62: 829-830.
[29] Coppola G, Lanzillo R, Florio C et al (2006) Long-Term Clinical Experience with
Weekley Interferon ß-1a in Relapsing Multiple Sclerosis. Eur. j. neurol. 13: 1014-1021.
[30] Hansson GK (2007) Light Hits the Liver. Science 316: 206-207.
[31] Glass CK, Saijo, K (2008) Oxysterols Hold T Cells in Check. Nature 455:40-41.
[32] Michalek RD, Gerriets VA, Jacobs SR et al (2011) Cutting Edge: Distinct Glycolytic and
Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T
Cells Subsets. J. immunol. 186: 3299-3303.
Lipoproteins – Role in Health and Diseases
578
[33] Henderson APD, Barnett MH, Parratt JDE et al (2009) Multiple Sclerosis – Distribution
of Inflammatory Cells in Newly Forming Lesions. Ann. neurol. 66: 739-753.
[34] Weber MS, Prod’homme T, Ypussef S. et al (2007) Type II Monocytes Modulate T Cell-
Mediated Central Nervous System Autoimmune Disease. Nat. med. 13: 935-943.
[35] Chinetti-Gbaguidi G, Staels B (2011) Macrophage Polarization in Metabolic Disorders:
Functions and Regulation. Curr. opin. lipidol. 22: 365-372.
[36] Newcombe J, Li H, Cuzner ML (1994) Low Density Lipoprotein Uptake by
Macrophages in Multiple Sclerosis Plaques: Implications for Pathogenesis.
Neuropathol. appl. neurobiol. 20: 152-162.
[37] Boven LA, Van Mars M, Van Zwam M et al (2006) Myelin-Laden Macrophages Are
Anti-Inflammatory with Foam Cells in Multiple Sclerosis. Brain 129: 517-526.
[38] Baitsch D, Bock HH, Engel T et al (2011) Apolipoprotein E Induces Antiinflammatory
Phenotype in Macrophages. Arterioscler. thromb. vasc. biol. 31: 1160-1168.
[39] Ecker J, Liebisch G, Englmaier M et al (2010) Induction of Fatty Acids Synthesis is a Key
Requirement for Phagocytic Differentiation of Human Monocytes. Proc. natl. acad. sci.
USA 107: 7817-7822.
[40] Pocivavsek A, Michailenko I, Strickland DK et al (2009), Microglial Low-Density
Lipoprotein Receptor-Related Protein 1 Modulates c-Jun N-Terminal Kinase Activation.
J. neuroimmunol. 214: 25-32.
[41] Gaultier A, Wu X, Le Moan N et al (2008) Low-Density Lipoprotein Receptor-Related
Protein 1 Is An Essencial Receptor for Myelin Phagacytosis. J. cell sci. 122: 1155-1162.
[42] Yepes M, Sandkvist M, Moore EG et al (2003) Tissue-Type Plasminogen Activator
Opening of the Blood-Brain Barrier Via the LDL Receptor-RelatedProtein. J. clin. invest.
112:1533-1540.
[43] Li F-Q, Sempowski GD, McKenna SE et al (2006) Apolipoprotein E-derived Peptides
Ameliorate Clinical Disability and Inflammatory Infiltrates into the Spinal Cord in a
Murine Model of Multiple Sclerosis. J pharmacol. exp. ther. 318: 956-965.
[44] Sena A, Tavares A, Ferret-Sena V et al (2008) Peroxisome Proliferator-Activated
Receptors (PPARs) in Relapsing-Remitting Multiple Sclerosis Patients. Mult. scler. 14:
S244.
[45] Shukla DK, Kaiser CC, Stebbins GT et al (2010) Effects of Poliglitazone on Diffusion
Tensor Imaging Indices in Multiple Sclerosis Patients. Neuroscience Letters 472: 153-
156.
[46] Cockerill GW, Rye KA, Gamble JR et al (1995) High-Density Lipoproteins Inhibit
Cytocine-Induced Expression of Endothelial Cell Adhesion Molecules. Arterioscler.
thromb. vasc. biol. 15: 1987-1994.
[47] Nobrega C, Capela C, Gorjon A et al (2011) Plasma Lipoproteins and Intrathecal
Immunoglobulin Synthesis in Multiple Sclerosis. J. neurol. 258 (Suppl 1): S202.
[48] Sarov-Blat, L, Kiss RS, Haidar B et al (2007) Predominance of a Proinflammatory
Phenotype in Monocyte-Derived Macrophages from Subjects with Low Plasma HDLCholesterol.
Arterioscler. thromb. vasc. biol. 27: 1115-1122.
Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases
579
[49] Mehling M, Johnson TA, Antel J (2011) Clinical Immunology of the Sphongosine 1-
Phosphate Receptor Modulator Fingolimod (FTY720) in Multiple Sclerosis. Neurology,
76 (Suppl 3): S20-S27.
[50] Norimatsu Y, Ohmori T, Kimura A et al (2012) FTY720 Improves Functional Recovery
after Spinal Cord Injury by Primarily Nonimmunomodulatory Mechanisms. Am. J.
pathol. 180: 1625-1635.
[51] Ferretti G, Bacchetti T (2011) Peroxidation of Lipoproteins in Multiple Sclerosis. J.
neurol. sci. 311: 92-97
[52] Haider L, Fisher MT, Frischer JM et al (2011) Oxidative Damage in Multiple Sclerosis
Lesions. Brain 134: 1914-1924.
[53] Sena A, Pedrosa R, Roque R et al (2006) Oxidised Low Density Lipoprotein in Serum of
Relapsing-Remitting Multiple Sclerosis Patients. Mult. scler. 12 (Suppl 1): S168-S169.
[54] Koch M, Mostert J, Arutjunyan AV et al (2007) Plasma Lipid Peroxidation and
Progression of Disability in Multiple Sclerosis. Eur. j. neurol. 14: 529-533.
[55] Mossberg N, Movitz C, Hellstrand K et al (2009) Oxygen Radical Production in
Leukocytes and Disease Severity in Multiple Sclerosis. J. immunol. 213: 131-134.
[56] Linker RA, Lee D-H, Ryan S et al (2011) Fumaric Acid Esters Exert Neuroprotective
Effects in Neuroinflammation Via Activation of the Nrf2 Aantioxidante Pathway. Brain
134: 678-692.
[57] Ludewig B, Laman JD (2004) The In and Out of Monocytes in Atherosclerotic Plaques:
Balancing Inflammation through Migration. Proc. natl. acad. sci. USA 101: 11529-11530.
[58] D’haesseleer M, Cambron M, Vanopdenbosch L et al (2011) Vascular Aspects of
Multiple Sclerosis. Lancet neurol. 10: 657-666.
[59] Sena A, Pedrosa R, Morais MG (2003) Therapeutical Potential of Lovastatin in Multiple
Sclerosis. J. neurol. 250: 754-755.
[60] Vollmer T, Key L, Durkalski V et al (2004) Oral Simvastatin Treatment in Relapsing-
Remitting Multiple Sclerosis. Lancet, 363: 1607-1608.
[61] Sena A, Pedrosa R, Morais MG (2007) Beneficial Effect of Statins in Multiple Sclerosis: Is
It Dose-Dependent? Atherosclerosis, 191: 462.
[62] Tskiri A, Lakkenbach K, Fuglø D et al (2011) Simvastatin Improves Final Visual
Outcome in Acute Optic Neuritis: a Randomized Study. Mult. scler. j. 18: 72-81.
[63] Waubant E, Pelletier D, Mass M et al (2012) Randomized Controlles Trial of
Atorvastatin in Clinically Isolated Syndrome. Neurology 78:1171-1178.
[64] Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: High-
Avidity Binding to ß-Amyloid and Increased Frequency of Type 4 Allele in Late-Onset
Alzheimer Disease. Proc. natl. acad. sci. USA 90: 1977-1981.
[65] Corder EH, Saunders AM, Strittmatter WJ (1993) Gene Dose of Apolipoprotein E Type 4
Allele and the Risk of Alzheimer’s Disease in Late-Onset Families. Science 261:921-931.
[66] Bu G, (2009) Apolipoprotein E and its Receptors in Alzheimer’s Disease: Pathways,
Pathogenesis and Therapy. Nat. rev. neuroscience 10: 333-344.
[67] Di Paolo G, Kim T-W (2011) Linking Lipids to Alzheimer’s Disease. Cholesterol and
Beyond. Nat. rev. neuroscience 12: 284-296.
Lipoproteins – Role in Health and Diseases
580
[68] Haan MN (2010) Midlife Cholesterol Level and Dementia 32 Years Later. Is There a
Risk? Neurology 75: 1862-1863.
[69] Mielke MM, Zandi PP, Shao H (2010) The 32-Year Relationship Between Cholesterol
and Dementia from Midlife to Late Life. Neurology 75: 1888-1895.
[70] Reitz C, Tang M-X, Schupf N et al (2010) Association of Higher Levels of High-Density
Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer
Disease. Arch. neurol. 67: 1491-1497.
[71] Singh-Manoux A, Gimeno D, Kivimaki M et al (2008) Low HDL Cholesterol Is a Risk
Factor for Deficit and Decline in Memory in Midlife. The Whitehall II Study.
Arterioscler. thromb. vasc. biol. 28: 1556-1562.
[72] Merched A, Xia Y, Visvikis S et al (2000) The Relation Between Apolipoprotein AI and
Dementia. The Honolulu-Asia Aging Study. Am. j. epidemiol. 165: 985-992.
[73] Kutiyama M, Takahashi K, Yamano T et al (1994) Low Levels of Serum Apolipoprotein
AI and AII in Senile Dementia. Jpn j. psychiatry neurol. 48: 589-593.
[74] Matsuzaki T, Sasaki K, Hata J et al (2011) Association of Alzheimer Disease Pathology
with Abnormal Lipid Metabolism. The Hisayama Study. Neurology 77: 1068-1075.
[75] Van Vliet p, Westendorp RGJ, Eikelenboom P et al ( 2009) Parental History of
Alzheimer Disease Associated with Lower Plasma Apolipoprotein E Levels. Neurology
73: 681-687.
[76] Gupta VB, Laws SM, Villemagne VL et al (2011) Plasma Apolipoprotein E and
Alzheimer Disease Risk. The AIBL Study of Aging. Neurology 76: 1091-1098.
[77] Kantarci K, Lowe V, Przybelski SA et al (2012) ApoE Modifies the Association Between
Aß Load and Cognition in Cognitively Normal Older Adults. Neurology 78: 232-240.
[78] Schrijvers EM, Koudstaal PJ, Hofman A et al (2011) Plasma Clusterin and the Risk of
Alzheimer Disease. Jama 305: 1322-1326.
[79] Holmes C, Cunningham C, Zotova E et al (2009) Systemic Inflammation and Disease
Progression in Alzheimer Disease. Neurology 73: 768-774.
[80] Iadecola C (2003) Atherosclerosis and Neurodegeneration. Unexpected Conspirators in
Alzheimer’s Dementia. Arterioscler. thromb. vasc. biol. 23: 1951-1953.
[81] Desai MK, Mastrangelo MA, Ryan DA et al (2010) Early Oligodendrocyte/Myelin
Pathology in Alzheimer’s Disease Mice Constitutes a Novel Therapeutic Target. Am. J.
pathol. 177: 1422-1435.
[82] Cramer PE, Cirrito JR, Wesson DW et al (2012) ApoE-Directed Therapeutics Rapidly
Clear ß-Amyloid and Reverse Deficits in AD Mouse Models. Science 335: 1503-1506.
[83] Takechi, R, Galloway S, Pallebage-Gamarallage MMS et al (2008) Chylomicron
Amyloid-Beta in the Aetiology of Alzheimer’s Disease. Atherosclerosis (Suppl 9) 19-25.
[84] Kontush A, Chapman MJ (2008) HDL: Close to Our Memories? Arterioscler. thromb.
vasc. biol. 28: 1418-1420.
[85] Elder GA, Cho JY, English DF et al (2007) Elevated Plasma Cholesterol. Does Not Affect
Brain Aß in Mice Lacking the Low-Density Lipoprotein Receptor. J. neurochem. 102:
1220-1231.
[86] Pistell PJ, Morrison CD, Gupta S et al (2010) Cognitive Impairment Following High Fat
Diet Consumption Is Associated with Brain Inflammation. J. immunol. 219: 25-32.
Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases
581
[87] Lieb W, Beiser AS, Vasan RS et al (2009) Association of Plasma Leptin Levels with
Incident Alzheimer Disease and MRI Measures of Brain Aging. Jama 302: 2565-2572.
[88] Une K, Takei A, Tomita N et al (2010) Adiponectin in Plasma and Cerebrospinal Fluid
in MCI and Alzheimer’s Disease. Eur. j. neurol. 18: 1006-1009.
[89] Yaffe K, Weston AL, Blackwell T et al (2009) The Metabolic Syndrome and
Development of Cognitive Impairment Among Older Women. Arch. neurol. 66: 324-
328.
[90] Craft S (2009) The Role of Metabolic Disorders in Alzheimer Disease and Vascular
Dementia. Arch. neurol. 66: 300-305.
[91] Brayne C, Ince PG, Keage H et al (2010) Education, the Brain and Dementia:
Neuroprotection or Compensation? Brain 133: 2210-2216.
[92] Belleville S, Clément F, Mellah S et al (2011) Training-Related Brain Plasticity in Subjects
at Risk of Development Alzheimer’s Disease. Brain 134: 1623-1634.
[93] Cuadrado-Godia E, Jiménez-Conde J, Ois A et al (2009) Sex Differences in the
Prognostic Value of the Lipid Profile After the First Ischemic Stroke. J. neurol. 256: 989-
995.
[94] Hughes TF, Borenstein AR, Schofield E et al (2009) Association Between Late-Life Body
Mass Index and Dementia. The Kame Project. Neurology 72: 1741-1746.
[95] Vidoni ED, Townley RA, Honea RA et al (2011) Alzheimer Disease Biomarkers Are
Associated with Body Mass Index. Neurology 77: 1913-1920.
[96] Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol Level and Statin Use in
Alzheimer Disease. I. Review of Epidemiological and Preclinical Studies. Arch. neurol.
68: 1239-1244.
[97] De Lau LML, Koudstaal PJ, Hofman A et al (2006) Serum Cholesterol Levels and the
Risk of Parkinson’s Disease. Am. j. epidemiol. 164: 998-1002.
[98] Huang X, Chen H, Miller WC et al (2007) Lower Low-Density Lipoprotein Cholesterol
Levels Are Associated with Parkinson’s Disease. Mov. disord. 22: 377-381.
[99] Hu G, Antikainen R, Jousilahti P et al (2008) Total Cholesterol and the Risk of Parkinson
Disease. Neurology 70: 1972-1979.
[100] Dupuis L, Corcia P, Fergani A et al (2008) Dyslipidemia Is a Protective Factor in
Amyotrophic Lateral Sclerosis. Neurology 70: 1004-1009.
[101] Chiò A, Calvo A, Ilardi A et al (2009) Lower Serum Lipids Are Related to Respiratory
Impairment in Patients with ALS. Neurology 73: 1681-1685.
[102] Glass CK; Saijo K, Winner B et al (2010) Mechanisms Underlying Inflammation in
Neurodegeneration. Cell140: 918-934.
[103] Valenza M, Cattaneo E (2011) Emerging Roles for Cholesterol in Huntington’s Disease.
Trends in neurosci. 34: 474-486.
[104] Whitehead AS, Bertrandy S, Finnan F et al (1996) Frequency of the Apolipoprotein E
e4 Allele in a Case-Control Study of Early Onset Parkinson’s Disease. J. neurol.
neurosurg. psychiatry (1996) 61: 347-351.
[105] Wilhelmus MMM, Bol JGJM, Rozemuller AJM et al (2011) Apolipoprotein E and LRP1
Increase Early in Parkinson’s Disease Pathogenesis. Am. J. pathol. 179: 2152-2156.
Lipoproteins – Role in Health and Diseases
582
[106] Thomas EA, Sutcliffe JG (2002) The Neurobiology of Apoliporoteins in Psichiatric
Disorders. Mol. Neurobiol. 26: 369-388.
[107] Muffat J, walker DW, Benzer S (2008) Human ApoD, an Up-Regulated in
Neurodegenerative Diseases, Extends Lifespan and Increases Stress Resistance in
Drosophila. Proc. natl. acad. sci. USA 105: 7088-7093.
[108] Terrise L, Poirier J, Bertrand P et al (1998) Increased Levels of Apolipoprotein D in
Cerebrospinal Fluid and Hippocampus of Alzheimer’s Patients. J. neurochem. 71: 1643-
1650.
[109] Digney A, Keriakous D, Scarr E et al (2005) Differential Changes in Apolipoprotein E
in Schizophrenia and Bipolar I Disorder. Biol. Psychiatry 57: 711-715.
[110] Huang JT-J, Wang L, Prabakaran S et al (2008) Independent Protein-Profiling Studies
Show a Decrease in Apolipoprotein AI Levels in Schizophrenia CSF, Brain and
Peripheral Tissues. Mol. psychiatry 13: 1118-1128.
[111] Zatorre RJ, Fields RD, Johansen-Berg H et al (2012) Plasticity in Gray and White:
Neuroimaging Changes in Brain Structure During Learning. Nat. rev. neurosci. 15: 528-
536.
[112] Karasinska JM, Rinninger F, Lütjohann et al (2009) Specific Loss of Brain ABCA1
Increases Brain Cholesterol Uptake and Influences Neuronal Structure and Function, J.
neurosci., 29: 3579-3589.
[113] Ruckh JM, Zhao J-W, Shadrach JL et al (2012) Rejuvenation of Regeneration in the
Aging Central Nervous System. Cell stem cell 10: 96-103.
[114] Redmond SA, Chan JR (2012) Revitalizing Remyelination–the Answer Is Circulating.
Science 336: 161-162.
[115] Cunnigham TJ, Yao L, Oetinger M et al (2006) Secreted Phospholipase A2 Activity in
Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J.
neuroinflammation 3: 26-33.
[116] Hesse D, Krakauer M, Lund H et al (2011) Disease Protection and Interleukin-10
Induction by Endogenous Interferon-ß in Multiple Sclerosis? Eur. j. neurol. 18: 266-272.
[117] Matarese G, Procaccini C, De Rosa V, (2008) The Intricate Interface Between Imuune
and Metabolic Regulation: a Role for Leptin in the Pathogenesis of Multiple Sclerosis? J.
leukoc. biol. 84: 893-899.
[118] Hietaharju A, Kuusisto H, Nieminen R et al (2010) Elevated Cerebrospinal Fluid
Adiponectin and Adipsin Levels in Patients with Multiple Sclerosis: a Finnish Co-Twin
Study. Eur. j. neurol. 17: 332-334.
[119] Sena A, Couderc R, Vasconcelos JC et al (2012) Oral Contraceptive Use and Clinical
Outcomes in Patients with Multiple Sclerosis. J. neurol. sci. 317(1-2): 47-51.
[120] Neu IS, Prosiegel M, Pfaffenrath V (1982) Platelet Aggregation and Multiple Sclerosis.
Acta neurol. scandinav. 66:497-504.
[121] Hawkes CH, (2007) Smoking is a Risk Factor for Multiple Sclerosis: a metanalysis.
Mult. scler. 13: 610-615.